Yutao Gong, PhD
Title
Cited by
Cited by
Year
Phase transitions in biogenic amorphous calcium carbonate
YUT Gong, CE Killian, IC Olson, NP Appathurai, AL Amasino, MC Martin, ...
Proceedings of the National Academy of Sciences 109 (16), 6088-6093, 2012
2312012
Mechanism of calcite co-orientation in the sea urchin tooth
CE Killian, RA Metzler, YUT Gong, IC Olson, J Aizenberg, Y Politi, FH Wilt, ...
Journal of the American Chemical Society 131 (51), 18404-18409, 2009
1852009
Self‐Sharpening Mechanism of the Sea Urchin Tooth
CE Killian, RA Metzler, Y Gong, TH Churchill, IC Olson, V Trubetskoy, ...
Advanced Functional Materials 21 (4), 682-690, 2011
782011
Prognostic value of the lung immune prognostic index for patients treated for metastatic non–small cell lung cancer
D Kazandjian, Y Gong, P Keegan, R Pazdur, GM Blumenthal
JAMA oncology 5 (10), 1481-1485, 2019
772019
Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton …
T Giaddui, W Chen, J Yu, L Lin, CB Simone, L Yuan, YUT Gong, QJ Wu, ...
Radiation oncology 11 (1), 1-7, 2016
592016
FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1
P Narayan, S Wahby, JJ Gao, L Amiri-Kordestani, A Ibrahim, E Bloomquist, ...
Clinical cancer research 26 (10), 2284-2289, 2020
462020
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
GM Blumenthal, Y Gong, K Kehl, P Mishra-Kalyani, KB Goldberg, ...
Annals of Oncology 30 (5), 830-838, 2019
442019
FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma
E Chang, C Weinstock, L Zhang, R Charlab, SE Dorff, Y Gong, V Hsu, F Li, ...
Clinical Cancer Research 27 (4), 922-927, 2021
192021
FDA approval summary: olaparib monotherapy or in combination with Bevacizumab for the maintenance treatment of patients with advanced ovarian cancer
S Arora, S Balasubramaniam, H Zhang, T Berman, P Narayan, D Suzman, ...
The Oncologist 26 (1), e164-e172, 2021
192021
Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients
L Shen, J van Soest, J Wang, J Yu, W Hu, YUT Gong, V Valentini, Y Xiao, ...
Oncotarget 6 (35), 38327, 2015
152015
FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
P Narayan, TM Prowell, JJ Gao, LL Fernandes, E Li, X Jiang, J Qiu, J Fan, ...
Clinical Cancer Research 27 (7), 1842-1849, 2021
142021
Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials
Y Gong, KL Kehl, GR Oxnard, S Khozin, PS Mishra-Kalyani, ...
Journal of Clinical Oncology 36 (suppl), abstr 9064, 2018
122018
FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer
M Shah, S Wedam, J Cheng, MH Fiero, H Xia, F Li, J Fan, X Zhang, J Yu, ...
Clinical Cancer Research 27 (5), 1220-1226, 2021
112021
Exploration of baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC …
DG Kazandjian, Y Gong, H Kazandjian, R Pazdur, GM Blumenthal
Journal of Clinical Oncology 36 (suppl), abstr 3035, 2018
52018
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
JJ Gao, CL Osgood, Y Gong, H Zhang, EW Bloomquist, X Jiang, J Qiu, ...
Clinical Cancer Research 27 (8), 2126-2129, 2021
42021
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
MS Anscher, E Chang, X Gao, Y Gong, C Weinstock, E Bloomquist, ...
The oncologist 26 (2), 139-146, 2021
32021
An Analysis of Recent FDA Oncology Scientific Publications
JA Schneider, AC Miklos, J Onken, Y Gong, AM Calcagno, ...
The oncologist 25 (3), 266, 2020
32020
Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance
Y Gong, J Yu, D Pang, H Zhen, J Galvin, Y Xiao
Frontiers in Oncology 6, 2016
32016
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation …
DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ...
European Journal of Cancer 157, 140-152, 2021
22021
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
E Chang, L Pelosof, S Lemery, Y Gong, KB Goldberg, AT Farrell, ...
The oncologist 26 (10), e1786-e1799, 2021
22021
The system can't perform the operation now. Try again later.
Articles 1–20